The use of intralesional triamcinolone as treatment of primary cutaneous B-cell lymphomas

Primary cutaneous B-cell lymphomas (PCBCLs) are benign malignancies which rarely disseminate, with 5-year disease-specific survival ranging from 94% to 100%. They are commonly treated with excision, radiation, or chemotherapy, alone or in combination. Intralesional corticosteroid injection is an alternative that is cost-effective with minimal side-effects, although it is less-frequently utilized as a primary mode of treatment. The present study was undertaken to evaluate the experience of an academic medical center in using intralesional corticosteroid injection as first-line therapy for PCBCL.